CHEK2 产品
(Checkpoint Kinase 2 (CHEK2))
Categories
In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012].
antibodies-online.com stands for high-quality research products. Search, find and order tools with extensive validation data, images, references. Our scientific customer service is always at your disposal if you have any questions about the selection or application of our products.
Featured CHEK2 Categories
CHEK2 抗体
High quality antibodies with extensive validation data.
CHEK2 ELISA试剂盒
Reliable ELISA kits for a wide range of species.
CHEK2 蛋白
Proteins for various applications incl. WB, ELISA, IF etc.
Recommended CHEK2 抗体
Product
Reactivity
Application
Validations
Cat. No.
Quantity
Datasheet
Reactivity
Human, Mouse, Rat
Application
WB, ELISA, IHC, IF, ICC
Validations
- (1)
- (10)
Cat. No.
ABIN6256554
Quantity
100 μL
Datasheet
Datasheet
Reactivity
Human
Application
WB, IP
Validations
- (7)
Cat. No.
ABIN950070
Quantity
100 μL
Datasheet
Datasheet
Reactivity
Human
Application
WB, ELISA, IF, IHC (p)
Validations
- (6)
Cat. No.
ABIN564867
Quantity
100 μg
Datasheet
Datasheet
Recommended CHEK2 ELISA试剂盒
Product
Reactivity
Analytical Method
Validations
Cat. No.
Quantity
Datasheet
Reactivity
Human
Analytical Method
Qualitative Cell ELISA
Validations
Cat. No.
ABIN1380543
Quantity
2 x 96 tests
Datasheet
Datasheet
Reactivity
Human, Mouse, Rat
Analytical Method
Qualitative Cell ELISA
Validations
Cat. No.
ABIN1380343
Quantity
2 x 96 tests
Datasheet
Datasheet
Reactivity
Human, Mouse, Rat
Analytical Method
Qualitative Cell ELISA
Validations
Cat. No.
ABIN1380544
Quantity
2 x 96 tests
Datasheet
Datasheet
Recommended CHEK2 蛋白
Product
Reactivity
Source
Validations
Cat. No.
Quantity
Datasheet
Reactivity
Human
Source
Wheat germ
Validations
- (2)
- (1)
Cat. No.
ABIN1349305
Quantity
10 μg
Datasheet
Datasheet
Reactivity
Human
Source
Wheat germ
Validations
- (1)
Cat. No.
ABIN1349307
Quantity
10 μg
Datasheet
Datasheet
Reactivity
Human
Source
Baculovirus infected Insect Cells
Validations
- (1)
Cat. No.
ABIN7317121
Quantity
50 μg
Datasheet
Datasheet
Latest Publications for our CHEK2 Products
: "Garlic Extract Alleviates Trastuzumab-Induced Hepatotoxicity in Rats Through Its Antioxidant, Anti-Inflammatory, and Antihyperlipidemic Effects." in: Journal of inflammation research, Vol. 14, pp. 6305-6316, (2021) (PubMed).: "Silica nanoparticle exposure inducing granulosa cell apoptosis and follicular atresia in female Balb/c mice." in: Environmental science and pollution research international, Vol. 25, Issue 4, pp. 3423-3434, (2018) (PubMed).
: "Endosulfan induces cell dysfunction through cycle arrest resulting from DNA damage and DNA damage response signaling pathways." in: The Science of the total environment, Vol. 589, pp. 97-106, (2017) (PubMed).
: "Deficiency of 53BP1 inhibits the radiosensitivity of colorectal cancer." in: International journal of oncology, Vol. 49, Issue 4, pp. 1600-8, (2017) (PubMed).
: "53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway." in: Journal of cancer research and clinical oncology, Vol. 143, Issue 3, pp. 419-431, (2017) (PubMed).
: "1,2:5,6-dianhydrogalactitol inhibits human glioma cell growth in vivo and in vitro by arresting the cell cycle at G2/M phase." in: Acta pharmacologica Sinica, Vol. 38, Issue 4, pp. 561-570, (2017) (PubMed).
: "ATM Signaling Pathway Is Implicated in the SMYD3-mediated Proliferation and Migration of Gastric Cancer Cells." in: Journal of gastric cancer, Vol. 17, Issue 4, pp. 295-305, (2017) (PubMed).
: "New origin firing is inhibited by APC/CCdh1 activation in S-phase after severe replication stress." in: Nucleic acids research, Vol. 44, Issue 10, pp. 4745-62, (2016) (PubMed).
: "The molecular mechanism of G2M cell cycle arrest induced by AFB1 in the jejunum." in: Oncotarget, Vol. 7, Issue 24, pp. 35592-35606, (2016) (PubMed).
: "Centrosome aberrations in human mammary epithelial cells driven by cooperative interactions between p16INK4a deficiency and telomere-dependent genotoxic stress." in: Oncotarget, Vol. 6, Issue 29, pp. 28238-56, (2015) (PubMed).
Synonyms and alternative names related to CHEK2
checkpoint kinase 2 (CHEK2), checkpoint kinase 2 (chek2), checkpoint kinase 2 (Chek2), serine/threonine-protein kinase chk2 (MCYG_07308), checkpoint kinase 2 L homeolog (chek2.L), CDS1, Cds1, cds1, chek2, CHK2, Chk2, chk2, fa66f08, hCds1, HuCds1, HUCDS1, hucds1, LFS2, lfs2, PP1425, pp1425, RAD53, Rad53, rad53, wu:fa66f08, zgc:55865Protein level used designations for CHEK2
- CHK2 checkpoint homolog
- cds1 homolog
- checkpoint-like protein CHK2
- serine/threonine-protein kinase Chk2
- protein kinase CHK2
- checkpoint and tumor suppressor protein 2
- Cds1 homolog
- Rad53 homolog
- protein kinase Chk2
- CHK2 checkpoint homolog (S. pombe)
- serine/threonine-protein kinase Chk2-like
- serine/threonine-protein kinase chk2
- checkpoint kinase 2 L homeolog
- protein kinase Cds1
You are here:
